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Spastic cerebral palsy (CP) is one of the most difficult and disabling conditions 
that requires medical attention and treatment. The aim of this study was to 
assess the efficacy and safety of oral tizanidine in treating spasticity in children 
with spastic CP.
Materials & Methods
Sixty children with spastic cerebral palsy were enrolled in a double-blind, 
placebo-controlled, randomized clinical trial. These patients were randomly 
assigned to receive tizanidine or a matching placebo. Sample normalization 
was not performed either before or after the study in these two separate groups. 
Nevertheless, no significant statistical difference was found between the two 
concerned groups in terms of age, sex, or type of spasticity. Each patient 
received the treatment for 2 weeks between May 2010 and February 2011. 
Results
Thirty-one boys and 29 girls with a mean age of 7.3 ± 3.4 years were evaluated. 
Our study revealed that spasticity was reduced in 50% of the patients receiving 
the drug tizanidine compared to only 6.7% of the patients receiving the placebo. 
Additionally, 66.7% of patients reported less pain on the affected side receiving 
tizanidine (group A) compared to 13.3% of patients receiving the placebo 
(group B). No serious side effects were reported in this study.
Conclusion
Tizanidine is effective and safe in decreasing the spastic hypertonia associated 
with cerebral palsy in children.
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Introduction
Spastic cerebral palsy (CP) is one of the most disabling conditions in children. 
Indeed, CP is a nonspecific descriptive term pertaining to disordered motor function 
evident during the early infant stage. CP is characterized by changes in muscle 
tone (typically spasticity) and certain neurological abnormalities, such as ataxia, 
abnormal movements, and sensory, behavioral, and cognitive dysfunction (1). CP 
occurs in 1.2 to 2.5 children per 1000 live births, premature birth being the single 
most important risk factor (2,3). CP can be classified into two types: the predominant 
type of motor abnormality, which is further classified into six forms (spastic, 
choreathetotic, dystonic, hypotonic, ataxic, and mixed) and the distribution of limb 
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involvement into three forms (hemiplegic, diplegic, and 
quadriplegic) (4,5,6). 
Many treatments have been proposed to treat spasticity 
under the assumption that spasticity is the main factor 
causing motor dysfunction and disability (7).
Tizanidine is an imidazole derivative in the same class as 
clonidine, which is known to be a potent α2-agonist (8). 
It is reported to be a presynaptic inhibitor that reduces 
the release of excitatory amino acids such as glutamate 
and aspartate. The drug may also facilitate the action of 
the inhibitory neurotransmitter glycine (9). Some of the 
most common side effects of tizanidine are dry mouth, 
sedation, dizziness, and hypotension.8 In this case, 
sedation may be a beneficial side effect if the drug is 
being used to improve spasms and comfort at night(10). 
Following two studies that have reported outcomes 
of tizanidine treatment in children with CP (11), we 
decided to evaluate the efficacy and safety of tizanidine 
for the treatment of spasticity in children affected with 
CP living in Tehran, Iran.
Materials & Methods
This double-blind, placebo-controlled, randomized 
clinical trial was conducted on children between the 
ages of 2 and 14 with spastic CP, who were referred to 
the pediatric neurology clinic at the children´s medical 
center between May 2010 and Feb 2011. The sample size 
of children with spastic CP was assessed to be 60 based 
on Z formula and a confidence interval (CI) of 95% with 
20% power to detect any significant difference between 
two groups (A & B) with a level of 0.05. These patients 
were enrolled into two different groups (30 patients in 
each group) via balanced block randomization. Sample 
normalization was not performed either before or after 
the study in these two separate groups. Nevertheless, 
no significant statistical difference was found between 
the two concerned groups in terms of age, sex, or type 
of spasticity. Specifically, our main objective was 
to evaluate the efficacy of tizanidine on decreasing 
spasticity. Patients in group A received tizanidine (2 mg/
day for age <7 years old and 4 mg/day for age >7 years 
old) and patients in group B received a matched placebo. 
We examined the patients before drug administration 
and assessed the severity of spastic hypertonicity using 
the Modified Ashworth Scale (MAS) (Table 1). After 
2 weeks of drug administration, we re-examined these 
patients and the new scores were compared with the 
previous scores. Additionally, we evaluated the reduction 
in pain sensation after drug or placebo administration 
based on historical information and subjective sensation 
of patients or their parents’ assessment. 
Chi-square or Fisher exact tests were used for data 
analysis of qualitative variables and mean values were 
compared using a t-test. This study was approved by 
the Ethics Committee of Tehran University of Medical 
Sciences, Tehran, Iran.
Results
The efficacy and safety of tizanidine was evaluated in 
children with spastic CP. Thirty-one boys (51.7%) and 
29 girls (48.3%) with a mean age of 7.3 ± 3.4 year 
(range = 2–14 year) were included in this study. In the 
evaluation of group statistics and t-test for equality of 
means for age, sex, and type of spastic CP, there was no 
significant statistical difference between groups A and 
B (P > 0.1). Indeed, the two groups were similar with 
respect to these variables.
   After 2 weeks of treatment, the Ashworth Score on 
the affected side was decreased in 15 patients of group 
A (received tizanidine), whereas the score was only 
decreased in 2 patients of group B (received placebo) 
(50% vs. 6.7%). These results showed that there was a 
significant statistical difference between the two groups 
(P < 0.0001). Moreover, tizanidine was significantly 
better than the placebo for pain reduction in spastic upper 
and/or lower limbs (66.7% vs. 13.3%) (P < 0.0001) 
(Figs. 1, 2).
Discussion
The syndrome of spastic hypertonia develops when the 
supra segmental control over the spinal cord segmental 
reflexes is lost.12 Spasticity is defined as a motor disorder 
characterized by a velocity-exaggerated increase in 
tonic stretch reflexes (muscle tone) with exaggerated 
reflex responses resulting from hyperactivity of 
the stretch reflex(12). The most common cause of 
spasticity in childhood is cerebral palsy (CP) (13). 
 In this study, we evaluated the effect of tizanidine 
in treating spasticity in children with spastic CP. 
Tizanidine is an imidazole derivative and a potent α2-
The efficacy and safety of tizanidine in treating spasticity in children with cerebral palsy 
21Iran J Child Neurology   Vol5 No3 Summer  2011
The efficacy and safety of tizanidine in treating spasticity in children with cerebral palsy 
agonist.8 This drug is also a presynaptic inhibitor that 
reduces the release of excitatory amino acids such 
as glutamate and aspartate. It may also facilitate the 
action of the inhibitory neurotransmitter glycine (9).
In the present study, the Modified Ashworth Scale 
(MAS) was used to measure spastic hypertonia. In this 
scale, the resistance during passive muscle stretching 
at an unspecified velocity or body posture is evaluated 
(14). As mentioned in our study, the mean Ashworth 
score decreased in 50% of the patients receiving 
tizanidine versus 6.7% of patients receiving the placebo 
(P<0.0001). In a previous study by Maythaler et al. 
(2001), tizanidine treatment in 17 patients with spasticity 
due to acquired brain injuries significantly decreased the 
average Ashworth score for the affected side following 
4 weeks of treatment (P<0.001) (15). In a separate 
double-blind study by Vasquez et al. (2006), 10 children 
suffering from spastic CP were treated with tizanidine 
and 30 children received a placebo for a 6-month period. 
Children receiving the placebo were thereafter unified 
with the group receiving tizanidine. Of the patients in 
the group receiving tizanidine, 78.8% reported having 
reduced spasticity compared with only 7.6% patients 
receiving the placebo (P<0.0001)(16). More recently, 
Palazon Garcia et al. (2008) reported the effect of 
tizanidine in 45 children with spastic CP. Their studies 
show that tolerance of tizanidine was excellent in 79% 
of children and was found to be good by 93% of their 
parents based on subjective assessment (17). 
Unfortunately, there have been few and limited studies 
on the effect of tizanidine in children. Despite these 
limited evaluations, many neurologists recommend that 
tizanidine be considered for the treatment of spasticity 
in childhood CP.18 Additionally, our results show a 
statistically significant reduction in pain (66.7%) as 
opposed to only 13.3% in the placebo group, a study 
that was not directly related to amount of decrease in 
spasticity (P<0.0001). These findings have not been 
previously reported in the literature.
In conclusion,Tizanidine is an effective and safe drug 
for decreasing the spastic hypertonia associated with 
spastic CP in children. On the basis of our experimental 
findings, we conclude that tizanidine could be considered 
as a useful anti-spastic drug for the treatment of spastic 
CP in children.
Table 1: Modified Ashworth Scale Score(14)
Test Description                     Score        
Modified Ashworth Scale Score
No increase in muscle tone
Slight increase in 
tone with a catch and release or minimal 
resistance at end of range
As 1 but with minimal resistance through 
range following catch
More marked increase tone through 
ROM*









  *ROM:Range Of Motion
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Fig 1. Changes in Ashworth Score between two groups of 
treatment. (Grey = no change, Black = better).
Fig2. Changes in pain reduction between two groups of 
treatment. (Grey = no change, Black = better)
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